Patheon will divest OTCs
This article was originally published in The Tan Sheet
Executive Summary
A sale of its over-the-counter manufacturing business will allow Patheon to focus its resources and capital on high-margin prescription pharmaceutical products, the Canadian company reports April 17. The sale will include the assets of the Niagara-Burlington Operations business, consisting of facilities in Fort Erie and Burlington Gateway, as well as commercial operations at Burlington Century. "We believe that another company with a strategic focus on this specialized [OTC] market will be better positioned to grow these high-quality, well-established operations more profitably," the firm notes. To improve profitability of remaining Canadian sites, the company will transfer substantially all commercial production and development services at its York Mills site in Toronto to its site in Whitby, Ontario. Upon its purchase of the Whitby facility in 2001, Patheon became the sole manufacturer and supplier of Novartis Consumer Health's TheraFlu line (1"The Tan Sheet" March 26, 2001, p. 18)...
You may also be interested in...
Novartis TheraFlu Canadian Manufacturing Site Sold To Patheon
Patheon would become the sole manufacturer and supplier of Novartis Consumer Health's TheraFlu line under an agreement to purchase Novartis' Whitby, Ontario pharmaceutical manufacturing facility.
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.